Home / Intelligence / Webinars / Enabling Contracting Capabilities: Uncovering the What, When and How
Available On Demand
Is your company planning to begin commercial contracting or preparing to contract within a new channel?
If you are a leader in a pre-commercial or commercial emerging life sciences company facing these challenges, this webinar is designed for you.
Join our experts from TGaS Advisors, a division of Trinity Life Sciences, as we share what you need to know whether you are embarking on your commercial contracting journey or thinking about a new contracting channel such as payer contracting, provider contracting, specialty, etc.
Key Webinar Topics
- What capabilities need to be enabled for each of the typical Pricing & Contracting functions: Strategic Pricing & Contract Strategy, Proposal Development & Analytics, Government Pricing & Compliance, and Contract Administration?
- When should activities be implemented according to our contract readiness timeline?
- How should capabilities be enabled based on industry best practices?
- What are the seven keys to success?
Featuring
Dmitry Kublanov
Vice President,
Pricing, Contracting and Analytics
Justin Wutti
Director,
Pricing, Contracting and Analytics
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Blog
Learnings to Kick-Start 2025: Health Equity
Health equity continues to be a hot topic in the life sciences industry. ISPOR EU sessions addressed several key questions surrounding the impact of health equity on HTA decision-making, the methodologies that should be employed, and the opportunities and challenges of incorporating health equity into health technology assessment (HTA). Ahead of ISPOR EU, Trinity’s HTA […]
Read More
Blog
Maximum Fair Price Round 2: Passing the Baton
On January 20, 2025, CMS announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under IRA. With the outcomes of the first price “negotiations” announced only last August, the IRA MFP process is still in its early development and there remains uncertainty over how it will evolve […]
Read More
Blog
Solving the Cell & Gene Therapy Access Puzzle in the U.S.
Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence and high costs. As cell and gene therapies become available in new indications beyond […]
Read More